November 14, 2011 - Timothy Gardner (past-president of the American Heart Association) and Frank Sellke (Chairman of the Council on Cardiovascular Surgery and Anesthesia of the American Heart Association) review Cytograft’s first in human clinical results HERE.
July 15, 2011 - Cytograft highlighted in cover story in Medical Device Daily, found HERE.
June 27, 2011 - Dr. McAllister presents Cytograft's allogeneic vascular graft at the American Heart Association's prestigious Emerging Science series. The presentation can be found HERE.
June 20, 2011 - Cytograft publishes an article in Endovascular Today
December 8, 2010 - Dr. Nicolas L'Heureux, Cytograft's Chief Scientific Officer, opens and chairs the session Tissue Engineering and Regenerative Medicine in the Clinic at the North American meeting of TERMIS in Orlando, Florida.
November 22, 2010 - Dr. L'Heureux, co-founder and CSO of Cytograft, is featured in the "Industry Spotlight" of the Biomedical Engineering Society.
JOB OPPORTUNITIES

Cytograft Tissue Engineering is developing a state-of-the-art technology to produce tissue-engineered products[1]. The Company is growing rapidly and is currently running multiple clinical trials to evaluate its product Lifeline™, a completely biological and autologous tissue engineered vascular graft[2],[3]. These new vessels can be used as bypass grafts in patients who do not have suitable autologous vein/artery for bypass (heart or leg surgery, or as arteriovenous shunts for hemodialysis). Cytograft, which was recently recognized as one of the top 50 innovators by Scientific American[4], is a young company located in Novato, California (Marin) that provides a dynamic, open and flexible work environment to promote outstanding achievements. In return, we require a high level of drive, dedication and integrity from each of our employees.

[1] L'Heureux, N. et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 12, 361-365 (2006).

[2] L'Heureux, N., McAllister, T. N. & de la Fuente, L. M. Tissue-engineered blood vessel for adult arterial revascularization. N. Eng. J. Med. 357, 1451-1453 (2007).

[3] McAllister, T. N. et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet 373, 1440-1446 (2009).

[4] Scientific American 50 (2006).

Cytograft is currently fully staffed but visit this page often as we post openings regularly to keep up with the company's expansion.